Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
120.00    0.60 (0.50%)
Bid:
119.40
Ask:
120.00
Spread: 0.60 (0.503%)
Market Cap: £292.10m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

PRTC to Present at Virtual Needham Conference

14 Apr 2020 07:00

RNS Number : 4591J
PureTech Health PLC
14 April 2020
 

14 April 2020

PureTech Health plc

 

PureTech to Present at 19th Annual Virtual Needham Healthcare Conference

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") today announced that Daphne Zohar, founder and chief executive officer, will present at the 19th Annual Virtual Needham Healthcare Conference on Wednesday, 15 April, at 1:30 PM EDT. The conference is being held virtually, and a webcast of the presentation will be available on the Investors Relations section of the PureTech website at https://www.puretechhealth.com/reports-presentations.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

 

US media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

Tom Donovan

+1 857 559 3397

tom@tenbridgecommunications.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFFFELSLILLII
Date   Source Headline
10th Oct 20229:45 amRNSForm 8.5 (EPT/NON-RI) PureTech Health Plc
10th Oct 20229:18 amRNSForm 8.5 (EPT/RI)
10th Oct 20227:00 amRNSTransaction in Own Shares
7th Oct 20227:00 amRNSTransaction in Own Shares
7th Oct 20227:00 amRNSStatement re Possible Offer
6th Oct 20227:00 amRNSTransaction in Own Shares
5th Oct 20227:00 amRNSTransaction in Own Shares
4th Oct 20227:00 amRNSTransaction in Own Shares
3rd Oct 20227:00 amRNSTransaction in Own Shares
29th Sep 20227:00 amRNSTransaction in Own Shares
28th Sep 20227:00 amRNSTransaction in Own Shares
27th Sep 20227:00 amRNSTransaction in Own Shares
26th Sep 20227:00 amRNSTransaction in Own Shares
23rd Sep 20227:00 amRNSTransaction in Own Shares
22nd Sep 20227:00 amRNSTransaction in Own Shares
21st Sep 20227:00 amRNSTransaction in Own Shares
19th Sep 20227:00 amRNSTransaction in Own Shares
16th Sep 20227:00 amRNSTransaction in Own Shares
15th Sep 20227:00 amRNSTransaction in Own Shares
14th Sep 20227:00 amRNSTransaction in Own Shares
13th Sep 20227:00 amRNSTransaction in Own Shares
12th Sep 20227:00 amRNSTransaction in Own Shares
9th Sep 20227:00 amRNSTransaction in Own Shares
8th Sep 202212:00 pmRNSPRTC to Present at Morgan Stanley Healthcare Conf
8th Sep 20227:00 amRNSTransaction in Own Shares
7th Sep 20227:00 amRNSTransaction in Own Shares
6th Sep 20227:00 amRNSTransaction in Own Shares
5th Sep 20227:00 amRNSPRTC LYT-100 Data & IPF Trial Design at ERS Conf
5th Sep 20227:00 amRNSTransaction in Own Shares
2nd Sep 20227:00 amRNSTransaction in Own Shares
1st Sep 20227:00 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTransaction in Own Shares
31st Aug 20227:00 amRNSTransaction in Own Shares
30th Aug 20227:00 amRNSTransaction in Own Shares
26th Aug 20227:00 amRNSTransaction in Own Shares
25th Aug 202212:05 pmRNSGLS Data: Candidate Improved Insulin Sensitivity
25th Aug 20227:01 amRNSHalf-year Report
25th Aug 20227:00 amRNSTransaction in Own Shares
24th Aug 20224:05 pmRNSPRTC's Sonde Partners with Koye Pharmaceuticals
24th Aug 20227:00 amRNSTransaction in Own Shares
23rd Aug 20227:00 amRNSTransaction in Own Shares
22nd Aug 20227:00 amRNSPRTC's Akili to Debut on Nasdaq
22nd Aug 20227:00 amRNSTransaction in Own Shares
19th Aug 20227:00 amRNSTransaction in Own Shares
18th Aug 20227:00 amRNSTransaction in Own Shares
17th Aug 20227:00 amRNSTransaction in Own Shares
15th Aug 20227:00 amRNSTransaction in Own Shares
9th Aug 20227:00 amRNSPRTC Receives $115M from Founded Entity Shares
9th Aug 20227:00 amRNSTransaction in Own Shares
8th Aug 202212:21 pmRNSKaruna Successful Ph3 KarXT Study in Schizophrenia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.